Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.

J Neurooncol. 2019 Jul 19. doi: 10.1007/s11060-019-03246-4. [Epub ahead of print]

PMID:
31325144
2.

Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study.

Steidl E, Müller M, Müller A, Herrlinger U, Hattingen E.

J Neurooncol. 2019 Jul 18. doi: 10.1007/s11060-019-03244-6. [Epub ahead of print]

PMID:
31321614
3.

PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib.

Weller JM, Keil VC, Gielen GH, Herrlinger U, Schäfer N.

Am J Med Genet A. 2019 Jul 10. doi: 10.1002/ajmg.a.61283. [Epub ahead of print]

PMID:
31291054
4.

Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.

Potthoff AL, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, Güresir Á, Güresir E, Joseph K, Pietsch T, Schuss P, Herrlinger U, Westhoff MA, Vatter H, Waha A, Schneider M.

Cancers (Basel). 2019 Jun 20;11(6). pii: E858. doi: 10.3390/cancers11060858.

5.

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.

Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group.

Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13.

PMID:
31203194
6.

Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.

Tzaridis T, Gepfner-Tuma I, Hirsch S, Skardelly M, Bender B, Paulsen F, Schaub C, Weller J, Schäfer N, Herrlinger U, Tabatabai G.

Neuro Oncol. 2019 Apr 23. pii: noz071. doi: 10.1093/neuonc/noz071. [Epub ahead of print] No abstract available.

PMID:
31089718
7.

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westphal M, Krex D, Schackert G, Tonn JC, Schlegel U, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M.

Acta Neuropathol Commun. 2019 Apr 25;7(1):59. doi: 10.1186/s40478-019-0704-8.

8.

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.

Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B, Glas M.

J Transl Med. 2019 Mar 20;17(1):96. doi: 10.1186/s12967-019-1846-y.

9.

Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12.

Giordano FA, Link B, Glas M, Herrlinger U, Wenz F, Umansky V, Brown JM, Herskind C.

Cancers (Basel). 2019 Feb 26;11(3). pii: E272. doi: 10.3390/cancers11030272. Review.

10.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
11.

Cross-sectional increase of adherence to multidisciplinary tumor board decisions.

Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, Güresir E, Schröck A, Far F, Pietsch T, Pantelis D, Thomas D, Vornholt S, Ernstmann N, Manser T, Neumann M, Funke B, Schmidt-Wolf IGH.

BMC Cancer. 2018 Sep 29;18(1):936. doi: 10.1186/s12885-018-4841-4.

12.

Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis.

Georgakis MK, Tsivgoulis G, Spinos D, Liaskas A, Herrlinger U, Petridou ET.

World Neurosurg. 2018 Dec;120:e818-e854. doi: 10.1016/j.wneu.2018.08.173. Epub 2018 Aug 30.

PMID:
30172970
13.

Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.

Georgakis MK, Tsivgoulis G, Spinos D, Dimitriou NG, Kyritsis AP, Herrlinger U, Petridou ET.

J Neurooncol. 2018 Nov;140(2):467-475. doi: 10.1007/s11060-018-2976-4. Epub 2018 Aug 16.

PMID:
30117023
14.

DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.

Witt H, Gramatzki D, Hentschel B, Pajtler KW, Felsberg J, Schackert G, Löffler M, Capper D, Sahm F, Sill M, von Deimling A, Kool M, Herrlinger U, Westphal M, Pietsch T, Reifenberger G, Pfister SM, Tonn JC, Weller M; German Glioma Network.

Neuro Oncol. 2018 Nov 12;20(12):1616-1624. doi: 10.1093/neuonc/noy118.

PMID:
30053291
15.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
16.

Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.

Kebir S, Rauschenbach L, Gielen GH, Schäfer N, Tzaridis T, Scheffler B, Giordano FA, Lazaridis L, Herrlinger U, Glas M.

J Clin Neurosci. 2018 Jul;53:255-258. doi: 10.1016/j.jocn.2018.04.056. Epub 2018 May 10.

PMID:
29754968
17.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

18.

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.

Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Langen KJ, Brandts C, Senft C, Harter PN, Bähr O.

Oncol Rep. 2017 Dec;38(6):3291-3296. doi: 10.3892/or.2017.6013. Epub 2017 Oct 2.

19.

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.

Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155. Erratum in: Neuro Oncol. 2018 Feb 19;20(3):434.

20.

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients.

Hattingen E, Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Herrlinger U, Glas M, Kebir S.

Oncotarget. 2017 Jun 27;8(32):53542-53551. doi: 10.18632/oncotarget.18612. eCollection 2017 Aug 8.

21.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

22.

Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial.

Herrlinger U, Schäfer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1815-1821. doi: 10.1007/s00432-017-2423-5. Epub 2017 Apr 22.

23.

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.

Neurology. 2017 Apr 11;88(15):1422-1430. doi: 10.1212/WNL.0000000000003809. Epub 2017 Mar 15.

24.

18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor.

Kebir S, Kimmich O, Niehusmann P, Gaertner FC, Essler M, Landsberg J, Klockgether T, Simon M, Herrlinger U, Glas M.

Oncol Lett. 2016 Dec;12(6):4705-4707. doi: 10.3892/ol.2016.5234. Epub 2016 Oct 10.

25.

Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov.

Cihoric N, Tsikkinis A, Minniti G, Lagerwaard FJ, Herrlinger U, Mathier E, Soldatovic I, Jeremic B, Ghadjar P, Elicin O, Lössl K, Aebersold DM, Belka C, Herrmann E, Niyazi M.

Radiat Oncol. 2017 Jan 3;12(1):1. doi: 10.1186/s13014-016-0740-5. Review.

26.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M.

Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

27.

Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.

Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E.

Cancer Med. 2017 Jan;6(1):89-99. doi: 10.1002/cam4.966. Epub 2016 Nov 28.

28.

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U, Glas M.

Neuro Oncol. 2016 Oct;18(10):1462-4. doi: 10.1093/neuonc/now154. Epub 2016 Sep 2. No abstract available.

29.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.

Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1825-9. doi: 10.1007/s00432-016-2187-3. Epub 2016 Jun 18.

PMID:
27318492
30.

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.

J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.

PMID:
27193554
31.

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.

Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21.

PMID:
27100354
32.

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schäfer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U.

Oncol Lett. 2016 Mar;11(3):2195-2198. Epub 2016 Feb 4.

33.

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma.

Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P.

J Clin Oncol. 2016 May 20;34(15):1757-63. doi: 10.1200/JCO.2015.64.9897. Epub 2016 Mar 14.

PMID:
26976424
34.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14.

PMID:
26976423
35.

Therapy of leptomeningeal metastasis in solid tumors.

Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M.

Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. Review.

PMID:
26827696
36.

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG.

Neuro Oncol. 2016 Apr;18(4):549-56. doi: 10.1093/neuonc/nov326. Epub 2016 Jan 27.

37.

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):321-322. doi: 10.1007/s00401-015-1523-z.

PMID:
26744347
38.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

39.

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y.

EMBO Mol Med. 2016 Jan 1;8(1):39-57. doi: 10.15252/emmm.201505505.

40.

Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):309-319. doi: 10.1007/s00401-015-1495-z. Epub 2015 Oct 22. Erratum in: Acta Neuropathol. 2016 Feb;131(2):321-2.

41.

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma.

Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5. Review.

42.

[Treatment of the glioma microenvironment].

Herrlinger U, Platten M.

Nervenarzt. 2015 Jun;86(6):684, 686-8, 690-1. doi: 10.1007/s00115-014-4225-1. Review. German.

PMID:
25962344
43.

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.

Korfel A, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M.

Neurology. 2015 Mar 24;84(12):1242-8. doi: 10.1212/WNL.0000000000001395. Epub 2015 Feb 25.

44.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

45.

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20.

PMID:
25411133
46.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

47.

Glioblastoma multiforme from diagnosis to death: a prospective, hospital-based, cohort, pilot feasibility study of patient reported symptoms and needs.

Golla H, Ale Ahmad M, Galushko M, Hampl J, Maarouf M, Schroeter M, Herrlinger U, Hellmich M, Voltz R.

Support Care Cancer. 2014 Dec;22(12):3341-52. doi: 10.1007/s00520-014-2384-z. Epub 2014 Aug 19.

PMID:
25135840
48.

Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.

Mack F, Schäfer N, Kebir S, Stuplich M, Schaub C, Niessen M, Scheffler B, Herrlinger U, Glas M.

Oncology. 2014;86(5-6):369-72. doi: 10.1159/000360295. Epub 2014 Jun 18.

PMID:
24942787
49.

Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.

Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M.

J Neurooncol. 2014 Apr;117(2):337-45. doi: 10.1007/s11060-014-1394-5. Epub 2014 Feb 7.

PMID:
24504501
50.

Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study.

Boström JP, Seifert M, Greschus S, Schäfer N, Glas M, Lammering G, Herrlinger U.

Strahlenther Onkol. 2014 Apr;190(4):416-21. doi: 10.1007/s00066-013-0505-0. Epub 2014 Jan 17.

PMID:
24429478

Supplemental Content

Loading ...
Support Center